Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Die Ophthalmologie
Erschienen in: Die Ophthalmologie 1/2021

23.07.2020 | DMARDs | Leitlinien, Stellungnahmen und Empfehlungen

Leitlinie Nr. 24a Uveitis intermedia

verfasst von: Berufsverband der Augenärzte Deutschlands e. V. (BVA), Deutsche Ophthalmologische Gesellschaft (DOG)

Erschienen in: Die Ophthalmologie | Sonderheft 1/2021

Einloggen, um Zugang zu erhalten

Auszug

Leitlinien sind Orientierungshilfen im Sinne von „Handlungs- und Entscheidungskorridoren“, von denen in begründeten Fällen abgewichen werden kann oder sogar muss. Sie beschreiben, was Augenärzte für eine angemessene Patientenversorgung in der Praxis für geboten halten. Dies entspricht in vielen Fällen nicht dem Leistungsniveau der gesetzlichen Krankenversicherung in Deutschland (s. Präambel). …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140:509–516PubMed
2.
Suhler EB, Lloyd MJ, Choi D et al (2008) Incidence and prevalence of uveitis in Veterans Affairs Medical Centers of the Pacific Northwest. Am J Ophthalmol 146:890–896PubMed
3.
Darrell RW, Wagener HP, Kurland LT (1962) Epidemiology of uveitis. Incidence and prevalence in a small urban community. Arch Ophthalmol 68:502–514PubMed
4.
Gritz DC, Wong IG (2004) Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 111:491–500PubMed
5.
Mortensen KK, Goldschmidt E (1981) Uveitis. Eine epidemiologische Untersuchung. Ber Zusammenkunft Dtsch Ophthalmol Ges 78: p:97–101
6.
Vadot E (1992) Epidemiology of intermediate uveitis: a prospective study in Savoy. Dev Ophthalmol 23:33–34PubMed
7.
Tran VT, Auer C, Guex-Crosier Y et al (1994) Epidemiological characteristics of uveitis in Switzerland. Int Ophthalmol 18:293–298PubMed
8.
Saari KM, Päivönsalo-Hietanen T, Vaahtoranta-Lehtonen H et al (1995) Epidemiology of endogenous uveitis in south-western Finland. Acta Ophthalmol 73:345–349
9.
Miettinen R (1977) Incidence of uveitis in Northern Finland. Acta Ophthalmol 55:252–260
10.
Manthey KF (1988) Intraokuläre Entzündungen. Ferdinand Enke Verlag, Stuttgart
11.
Jakob E, Reuland MS, Mackensen F et al (2009) Uveitis subtypes in a german interdisciplinary uveitis center—analysis of 1916 patients. J Rheumatol 36:12736
12.
McCannel CA, Holland GN, Helm CJ et al (1996) Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group. Am J Ophthalmol 121:35–46PubMed
13.
Boskovich SA, Lowdere CY, Meisler DM, Gutman FA (1993) Systemic diseases associated with intermediate uveitis. Cleve Clin J Med 60:460–465PubMed
14.
Bonfioli AA, Damico FM, Curi AL, Orefice F (2005) Intermediate uveitis. Semin Ophthalmol 20:147–154PubMed
15.
Vidovic-Valentincic N, Kraut A, Hawlina M et al (2009) Intermediate uveitis: long-term course and visual outcome. Br J Ophthalmol 93:477–480PubMed
16.
Heinz C, Schoonbrood S, Heiligenhaus A (2014) Intermediate uveitis in children and young adults: differences in clinical course, associations and visual course. Br J Ophthalmol 98:1107–1111PubMed
17.
Ness T, Boehringer D, Heinzelmann S (2017) Intermediate uveitis: pattern of etiology, complications, tretment and outcome in a tertiary academic center. Orphanet J Rare Dis 12:81PubMedPubMedCentral
18.
Malinowski SM, Pulido JS, Folk JC (1993) Long-term visual outcome and complications associated with pars planitis. Ophthalmology 100:818–824PubMed
19.
Stübiger N, Ruprecht K, Pleyer U (2018) Intraocular inflammation in multiple sclerosis. Ophthalmologe 115:531–542PubMed
20.
Fearnley IR, Rosenthal AR (1995) Fuchs’ heterochromic iridocyclitis revisited. Acta Ophthalmol Scand 73:166–170PubMed
21.
Jones NP (1991) Fuchs’ heterochromic uveitis: a reappraisal of the clinical spectrum. Eye (Lond) 5:649–661
22.
Mandeville JT, Levinson RD, Holland GN (2001) The tubulointerstitial nephritis and uveitis syndrome. Surv Ophthalmol 46:195–208PubMed
23.
Donaldson MJ, Pulido JS, Herman DC et al (2007) Pars planitis: a 20-year study of incidence, clinical features, and outcomes. Am J Ophthalmol 144:812–817PubMed
24.
Niederer RL, Sharief L, Bar A et al (2017) Predictors of long-term visual outcome in intermediate uveitis. Ophthalmology 124:393–398PubMed
25.
Nussenblatt RB, Palastine AG, Chan CC, Roberge F (1985) Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 92:467–471PubMed
26.
Tugal-Tutkun I, Herbort CP, Khairallah M et al (2010) Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol 30:539–552PubMed
27.
Quentin CD, Reiber H (2004) Fuchs heterochromic cyclitis: rubella virus antibodies and genome in aqueous humor. Am J Ophthalmol 138:46–54PubMed
28.
de Groot-Mijnes JD, de Visser L, Rothova A et al (2006) Rubella virus is associated with fuchs heterochromic iridocyclitis. Am J Ophthalmol 141:212–214PubMed
29.
Ang M, Hedayatfar A, Zhang R, Chee SP (2012) Clinical signs of uveitis associated with latent tuberculosis. Clin Experiment Ophthalmol 40:689–696PubMed
30.
Ruokonen PC, Metzner S, Ucer A et al (2010) Intraocular antibody synthesis against rubella virus and other microorganisms in Fuchs’ heterochromic cyclitis. Graefes Arch Clin Exp Ophthalmol 248:565–571PubMed
31.
Fox CP, Phillips EH, Smith J, Linton K, Gallop-Evans E, Hemmaway C, Auer DP, Fuller C, Davies AJ, McKay P, Cwynarski K (2019) Guidelines for the diagnosis and management of primary central nervous system diffuse large B‑cell lymphoma. British Society for Haematology. Br J Haematol 184:348–363PubMed
32.
Roesel M, Gutfleisch M, Heinz C et al (2009) Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study. Ophthalmic Res 42:81–86PubMed
33.
Gaudio PA (2004) A review of evidence guiding the use of corticosteroids in the treatment of intraocular inflammation. Ocul Immunol Inflamm 12:169–192PubMed
34.
Bae JH, Lee CS, Lee SC (2011) Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Retina 31:111–118PubMed
35.
Kok H, Lau C, Maycook N et al (2005) Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 112:1916 e1–1916 e7
36.
Angunawela RI, Heatley CJ, Williamson TH et al (2005) Intravitreal triamcinalone acetonide for refractory uveitic cystoid macular oedema: longterm management and outcome. Acta Ophthalmol Scand 83:595–599PubMed
37.
Lowder C, Belfort R Jr, Lightman S et al (2011) Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 129:545–553PubMed
38.
Winterhalter S, Ruokonen P, van der Velden KH et al (2011) Intravitreal implants: drug carriers and carriers of hope? Ophthalmologe 108:222–229PubMed
39.
Winterhalter S, Behrens UD, Salchow D, Joussen AM, Pleyer U (2017) Dexamethasone implants in paediatric patients with noninfectious intermediate or posterior uveitis: first prospective exploratory case series. BMC Ophthalmol 17:252PubMedPubMedCentral
40.
Tufail A, Lightman S, Kamal A et al (2018) Post-marketing surveillance study of the safety of dexamethasone intravitreal implant in patients with retinal vein occlusion or noninfectious posterior segment uveitis. Clin Ophthalmol 12:2519–2534PubMedPubMedCentral
41.
Pohlmann D, Vom Brocke GA, Winterhalter S et al (2018) Dexamethasone inserts in noninfectious uveitis: a single-center experience. Ophthalmology 125:108899
42.
Jaffe GJ, Lin P, Keenan RT et al (2016) Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posteriore uveitis, and panuveitis. Ophthalmology 123:1940–1948PubMed
43.
Jaffe GJ, Foster CS, Pavesio CE et al (2019) Effect of an injectable fluocinolone acetonide insert on recurrence rates in chronic noninfectious uveitis affecting the posterior segment: twelve-month results. Ophthalmology 126:601–610PubMed
44.
45.
Soheilian M, Rabbanikhah Z, Ramezani A et al (2010) Intravitreal bevacizumab versus triamcinolone acetonide for refractory uveitic cystoid macular edema: a randomized pilot study. J Ocul Pharmacol Ther 26:199–206PubMed
46.
Lasave AF, Schlaen A, Zeballos DG et al (2019) Twenty-four months follow-up of intravitreal bevacizumab injection versus intravitreal triamcinolone acetonide injection for the management of persistent non-infectious uveitic cystoid macular edema. Ocul Immunol Inflamm 27:294–302PubMed
47.
Taylor SR, Banker A, Schlaen A et al (2013) Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis. Retina 33:2149–2154PubMed
48.
Khalil HE, El Gendy HA, Youssef HA et al (2016) The effectiveness of intraocular methotrexate in the treatment of posterior uveitis in Behçet’s disease patients compared to retrobulbar steroids injection. J Ophthalmol 2016:1678495PubMedPubMedCentral
49.
Multicenter uveitis steroid treatment trial research group, Kempen JH, Altaweel MM et al (2010) The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol 149:550–561
50.
Cunningham ET Jr, Wender JD (2010) Practical approach to the use of corticosteroids in patients with uveitis. Can J Ophthalmol 45:352–358PubMed
51.
Chirikov VV, Shah R, Kwon Y, Patel D (2019) Oral corticosteroid exposure and increased risk of related complications in patients with noninfectious intermediate, posterior, or panuveitis: Real-world data analysis. Ophthalmic Epidemiol 26:27–46PubMed
52.
Taylor SR, Isa H, Joshi L, Lightman S (2010) New developments in corticosteroid therapy for uveitis. Ophthalmologica 224(Suppl 1):46–53PubMed
53.
Strehl C, Bijlsma JW, De Wit M et al (2016) Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task forcee. Ann Rheum Dis 75:952–957PubMed
54.
Dick AD, Rosenbaum JT, Al-Dhibi HA et al (2018) Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (FOCUS) initiative. Ophthalmology 125:757–773PubMed
55.
Whitcup SM, Csaky KG, Podgor MJ et al (1996) A randomized, masked, cross-over trial of acetazolamide for cystoid macular edema in patients with uveitis. Ophthalmology 103:1054–1062PubMed
56.
Schilling H, Heiligenhaus A, Laube T et al (2005) Long-term effect of acetazolamide treatment of patients with uveitic chronic cystoid macular edema is limited by persisting inflammation. Retina 25:182–188PubMed
57.
Pepple KL, Nguyen MH, Pakzad-Vaezi K et al (2019) Response of inflammatory cystoid macular edema to treatment using oral acetazolamide. Retina 39:948–955PubMedPubMedCentral
58.
Jabs DA, Rosenbaum JT, Foster CS et al (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130:492–513PubMed
59.
Esterberg E, Acharya NR (2012) Corticosteroid-sparing therapy: practice patterns among uveitis specialists. J Ophthalmic Inflamm Infect 2:21–28PubMed
60.
Galor A, Jabs DA, Leder HA et al (2008) Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 115:1826–1832PubMed
61.
de Vries J, Baarsma GS, Zaal MJ et al (1990) Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol 74:344–349PubMedPubMedCentral
62.
Kacmaz RO, Kempen JH, Newcomb C et al (2010) Cyclosporine for ocular inflammatory diseases. Ophthalmology 117:576–584PubMedPubMedCentral
63.
Nussenblatt RB, Palastine AG, Chan CC et al (1991) Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol 112:138–146PubMed
64.
Murphy CC, Greiner K, Plskova J et al (2005) Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 123:634–641PubMed
65.
Hogan AC, McAvoy CE, Dick AD, Lee RW (2007) Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 114:1000–1006PubMed
66.
Murphy CC, Greiner K, Plskova J et al (2007) Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis. Br J Ophthalmol 91:154–156PubMed
67.
Gangaputra S, Newcomb CW, Liesegang TL et al (2009) Methotrexate for ocular inflammatory diseases. Ophthalmology 116:2188–2198PubMedPubMedCentral
68.
Malik AR, Pavesio C (2005) The use of low dose methotrexate in children with chronic anterior and intermediate uveitis. Br J Ophthalmol 89:806–808PubMedPubMedCentral
69.
Rathinam SR, Gonzales JA, Thundikandy R et al (2019) Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA 322:936–945PubMedPubMedCentral
70.
Niemeyer KM, Gonzales JA, Rathinam SR et al (2017) Quality of life outcomes from a randomized clinical trial comparing antimetabolites for intermediate, posterior, and panuveitis. Am J Ophthalmol 179:10–17PubMedPubMedCentral
71.
Teoh SC, Hogan AC, Dick AD, Lee RW (2008) Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol 146:752–760PubMed
72.
Thorne JE, Jabs DA, Qazi FA et al (2005) Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 112:1472–1477PubMed
73.
Doycheva D, Zierhut M, Blumenstock G et al (2011) Long-term results of therapy with mycophenolate mofetil in chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 249:1235–1243PubMed
74.
Abu El-Asrar AM, Hemachandran S, Al-Mezaine HS et al (2012) The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease. Acta Ophthalmol 90:e603–8PubMed
75.
Doycheva D, Zierhut M, Blumenstock G et al (2012) Mycophenolate mofetil in the therapy of uveitic macular edema—long-term results. Ocul Immunol Inflamm 20:20311
76.
Lau CH, Comer M, Lightman S (2003) Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Experiment Ophthalmol 31:487–491PubMed
77.
Siepmann K, Huber M, Stübiger N et al (2006) Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol 244:788–794PubMed
78.
Deuter CME, Engelmann K, Heiligenhaus A et al (2018) Enteric-coated mycophenolate sodium in the treatment of non-infectious intermeditae uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. Br J Ophthalmol 102:647–653PubMed
79.
Pacheco PA, Taylor SR, Cuchacovich MT, Diaz GV (2008) Azathioprine in the management of autoimmune uveitis. Ocul Immunol Inflamm 16:161–165PubMed
80.
Yazici H, Pazarli H, Barnes CG et al (1990) A controlled trial of azathioprine in Behcet’s syndrome. N Engl J Med 322:281–285PubMed
81.
Greenwood AJ, Stanford MR, Graham EM (1998) The role of azathioprine in the management of retinal vasculitis. Eye (Lond) 12:783–788
82.
Pasadhika S, Kempen JH, Newcomb CW et al (2009) Azathioprine for ocular inflammatory diseases. Am J Ophthalmol 148:500–509PubMedPubMedCentral
83.
Roy M (2007) Early clinical experience with leflunomide in uveitis. Can J Ophthalmol 42:634PubMed
84.
Molina C, Modesto C, Martin-Begue N, Amal C (2013) Leflunomide, a valid and safe drug for the treatment of chronic anterior uveitis associated with juvenile idiopathic arthritis. Clin Rheumatol 32:1673–1675PubMed
85.
Bichler J, Benseler SM, Krumrey-Langkammerer M et al (2015) Leflunomide is associated with a higher flare rate compared to methotrexate in the treatment of chronic uveitis in juvenile idiopathic arthritis. Scand J Rheumatol 44:280–283PubMed
86.
Levy-Clarke G, Jabs DA, Read RW et al (2014) Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121:785–796PubMed
87.
Mackensen F, Max R, Becker MD (2009) Interferons and their potential in the treatment of ocular inflammation. Clin Ophthalmol 3:559–566PubMedPubMedCentral
88.
Deuter C, Stubiger N, Zierhut M (2012) Interferon-alphatherapy in noninfectious uveitis. Dev Ophthalmol 51:90–97PubMed
89.
90.
Velazquez-Villoria D, Macia-Badia C, Segura-García A et al (2017) Efficacy of immunomodulatory therapy with interferon‑β or glatiramer acetate on multiple sclerosis-associated uveitis. Arch Soc Esp Oftalmol 92:273–279PubMed
91.
Cordero-Coma M, Yilmaz T, Onal S (2013) Systematic Review of Anti-Tumor Necrosis Factor-alpha Therapy for Treatment of Immune-mediated Uveitis. Ocul Immunol Inflamm 21:12–20
92.
Rubbert-Roth A (2012) Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatol (Oxford) 51(Suppl 5):v38–47
93.
Suhler EB, Lowder CY, Goldstein DA et al (2013) Adalimumab therapy for refractory uveitis: results of a multicentre, opan-label, prospective trial. Br J Ophthalmol 97:481–486PubMed
94.
Calvo‑R ío V, Blanco R, Beltrán E et al (2014) Anti-TNF‑α therapy in patients with refractory uveitis due to Behçet’s disease: a 1-year follow-up study of 124 patients. Rheumatol (Oxford) 53:2223–2231
95.
Jaffe GF, Dick AD, Brezin AP et al (2016) Adalimumab in patients with active non-infectious uveitis: VISUAL‑1 Trial. N Engl J Med 375:932–943PubMed
96.
Vallet H, Riviere S, Sanna A et al (2015) (French Behç et Network) Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: Multicenter study of 124 patients. J Autoimmun 62:67–74PubMed
97.
Nguyen QD, Merrill PT, Jaffe GJ et al (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 388:1183–1192PubMed
98.
Suhler EB, Adan A, Brezin AP et al (2018) Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology 125:1075–1087PubMed
99.
Wendling D et al (2014) Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res Opin 30:2515–2521PubMed
100.
Maleki A, Sahawneh HF, Ma L et al (2017) Infliximab therapy in patients with noninfectious intermediate uveitis resistant to conventional immunomodulatory therapy. Retina 37:836–843PubMed
101.
Markomichelakis NN, Theodossiadis PG, Pantelia E et al (2004) Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 138:648–650PubMed
102.
Burmester GR, Landewe R, Genovese MC et al (2017) Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis 76:414–417
103.
Garcês S, Demengeot J, Benito-Garcia E (2013) The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 72:1947–1955PubMed
104.
Thomas SS, Borazan N, Barroso N et al (2015) Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis. BioDrugs 29:241–258PubMed
105.
Absasolo L, Rosales Z, Diaz-Valle D et al (2016) Immunosuppressive drugs discontinuation in noninfectious uveitis from real-life clinical practice: a survival analysis. Am J Ophthalmol 169:169–178
106.
Lerman MA, Lewen MD, Kempen JH, Mills MD (2015) Uveitis reactivation in children treated with tumor necrosis factor alpha inhibitors. Am J Ophthalmol 160:193200
107.
Kalinina Ayuso VK, van de Winkel EL, Rothova A et al (2011) Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol 151:217–222PubMed
108.
Shakoor A, Esterberg E, Acharya NR (2014) Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm 22:96–101PubMed
109.
Borrego-Sanz L, Abásolo L, López-Abad C et al (2018) Disease remission in children and adolescents with intermediate uveitis: a survival analysis. Ophthalmologica 239:151–158PubMed
110.
Kempen JH, Gewaily DY, Newcomb CW, Liesegang TL, Kaçmaz RO, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Sen HN, Suhler EB, Thorne JE, Foster CS, Jabs DA, Payal A, Fitzgerald TD, Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group (2016) Remission of Intermediate Uveitis: Incidence and Predictive Factors. Am J Ophthalmol 164:110–117PubMedPubMedCentral
111.
Becker M, Davis J (2005) Vitrectomy in the treatment of uveitis. Am J Ophthalmol 140:1096–1105PubMed
112.
Quinones K, Choi JY, Yilmaz T et al (2010) Pars plana vitrectomy versus immunomodulatory therapy for intermediate uveitis: A prospective, randomized pilot study. Ocul Immunol Inflamm 18:411–417PubMed
113.
Heiligenhaus A, Bornfeld N, Foerster MH, Wessing A (1994) Long-term results of pars plana vitrectomy in the management of complicated uveitis. Br J Ophthalmol 78:549–554PubMedPubMedCentral
114.
Park SE, Mieler WF, Pulido JS (1995) 2 peripheral scatter photocoagulation for neovascularization associated with pars planitis. Arch Ophthalmol 113:1277–80PubMed
115.
Pulido JS, Mieler WF, Walton D, Kuhn E, Postel E, Hartz A et al (1998) Results of peripheral laser photocoagulation in pars planitis. Trans Am Ophthalmol Soc 96:127–137PubMedPubMedCentral
116.
Ganesh SK, Babu K, Biswas J (2004) Phacoemulsification with intraocular lens implantation in cases of pars planitis. J Cataract Refract Surg 30:2072–2076PubMed
117.
Grzybowski A, Kanclerz P, Pleyer U (2017) Challenges with cataract surgery in pars planitis patients. Graefes Arch Clin Exp Ophthalmol 255:1483–1484PubMedPubMedCentral
118.
Kaufman AH, Foster CS (1993) Cataract extraction in patients with pars planitis. Ophthalmology 100:1210–1217PubMed
119.
Friedman DS, Holbrook JT, Ansari H et al (2013) Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial. Ophthalmology 120:1571–1579PubMedPubMedCentral
120.
Sen HN, Vitale S, Gangaputra SS et al (2014) Periocular corticosteroid injections in uveitis: effects and complications. Ophthalmology 121:2275–2286PubMedPubMedCentral
Metadaten
Titel
Leitlinie Nr. 24a Uveitis intermedia
verfasst von
Berufsverband der Augenärzte Deutschlands e. V. (BVA)
Deutsche Ophthalmologische Gesellschaft (DOG)
Publikationsdatum
23.07.2020
Verlag
Springer Medizin
Schlagwörter
DMARDs
Uveitis
Erschienen in
Die Ophthalmologie / Ausgabe Sonderheft 1/2021
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI
https://doi.org/10.1007/s00347-020-01171-w

Weitere Artikel der Sonderheft 1/2021

Die Ophthalmologie 1/2021 Zur Ausgabe

Leitlinien, Stellungnahmen und Empfehlungen

Statement of the German Ophthalmological Society (DOG), the German Retina Society (GRS), and the Professional Association of German Ophthalmologists (BVA) on anti-VEGF treatment in neovascular age-related macular degeneration

Leitlinien, Stellungnahmen und Empfehlungen

Statement of the German Ophthalmological Society, the German Retina Society, and the Professional Association of Ophthalmologists in Germany on treatment of diabetic macular edema

Leitlinien, Stellungnahmen und Empfehlungen

Bewertung von Risikofaktoren für das Auftreten des Offenwinkelglaukoms

Leitlinien, Stellungnahmen und Empfehlungen

Statement of the German Society of Ophthalmology, the German Retina Society, and the Professional Association of German Ophthalmologists on anti-VEGF therapy of retinopathy of prematurity

Leitthema

Eye changes in space

Erratum

Erratum zu: Bewertung von Risikofaktoren für das Auftreten des Offenwinkelglaukoms

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Therapieverfahren in der Augenheilkunde CME-Artikel

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Erkrankungen der Hornhaut CME-Artikel

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise